Literature DB >> 7805175

Vinblastine and erythromycin: an unrecognized serious drug interaction.

S W Tobe1, L L Siu, S A Jamal, K L Skorecki, G F Murphy, E Warner.   

Abstract

Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805175     DOI: 10.1007/BF00686546

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

Review 1.  Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research.

Authors:  G M Strauss; M P Langer; A D Elias; A T Skarin; D J Sugarbaker
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

Review 2.  Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens.

Authors:  D Raghavan; B Pearson; W H Watt; H Mameghan; P Langdon; D Eisinger; R Wines
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

3.  Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.

Authors:  C J Rodenburg; K Nooter; H Herweijer; C Seynaeve; R Oosterom; G Stoter; J Verweij
Journal:  Ann Oncol       Date:  1991-04       Impact factor: 32.976

4.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

5.  The effects of erythromycin in patients treated with cyclosporine.

Authors:  R Martell; D Heinrichs; C R Stiller; M Jenner; P A Keown; J Dupre
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

6.  Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.

Authors:  H W Herr; H I Scher
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

Review 7.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 8.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

9.  Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.

Authors:  E Warner; S W Tobe; I L Andrulis; Y Pei; J Trachtenberg; K L Skorecki
Journal:  Am J Clin Oncol       Date:  1995-06       Impact factor: 2.339

  9 in total
  1 in total

Review 1.  Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Authors:  R Heylen; R Miller
Journal:  Genitourin Med       Date:  1996-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.